Ert Pompe denied as non-formulary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for ert pompe are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies ERT for Pompe Disease as Non-Formulary

A non-formulary denial means the specific enzyme replacement therapy your physician prescribed is not included on UnitedHealthcare's preferred drug list for your plan tier, or it appears on a specialty tier that requires a separate formulary exception process. Because only a small number of ERTs are approved for Pompe disease, this denial often arises when a newer FDA-approved agent is not yet on the formulary, or when the formulary lists a different ERT than the one prescribed.

## Why This Denial Is Appealable

For ultra-rare diseases like Pompe disease, formulary exceptions are a well-established and frequently granted pathway. When no formulary alternative is clinically appropriate — because the formulary agent was tried and failed, caused adverse effects, or is not approved for your specific disease subtype — the plan is required to grant an exception. Refusing to cover the only clinically appropriate FDA-approved therapy for a serious genetic disease is a strong basis for both internal and external appeal.

## Federal Appeal Framework

• ERISA §503 (employer plans) requires a full-and-fair internal review of formulary exception requests.
• ACA §2719 entitles you to external review by an accredited IRO. Non-formulary denials that result in a failure to cover medically necessary care are reviewable externally.
• The external-review window is typically within approximately four months of the denial notice — check your Explanation of Benefits for the exact deadline.
• Expedited review is available; given Pompe disease's progressive nature, document clinical urgency explicitly.
• State law: Many states have additional formulary exception protections for rare-disease drugs; check your state insurance commissioner's resources.

## Concrete Appeal Steps

1. Request UHC's formulary exception request form — this is a separate, specific process from a standard appeal and is often faster. 2. Identify whether UHC's formulary lists any ERT for Pompe disease at all, and if so, which one. 3. Have your physician document why the formulary alternative is not appropriate for your case (different approval scope, prior inadequate response, or no alternative exists on the formulary). 4. If the formulary exception is denied, escalate to internal appeal and then external review.

## Documentation to Gather

• Diagnosis confirmation: Genetic report and enzyme assay confirming Pompe disease diagnosis.
• Prescriber justification letter: A letter from your metabolic specialist explaining why the prescribed ERT is medically necessary and why any formulary alternative is clinically inappropriate for this patient — referencing the FDA-approved indication for the specific agent.
• Prior-treatment history: If you previously received a different ERT and experienced inadequate response or adverse effects, document dates, clinical notes, and the reason for the switch.
• FDA label: A copy of the current prescribing information confirming the approved indication aligns with your diagnosis.
• Clinical severity documentation: Current functional status (pulmonary, motor) to establish urgency.

## Criteria-Mapping Structure

For a formulary exception, the key criteria are typically: (1) the prescribed drug is medically necessary; (2) the formulary alternative is contraindicated, previously failed, or unavailable for this indication. Map each:

| Exception Criterion | Your Evidence | |---|---| | Prescribed drug is FDA-approved for this indication | FDA label — indication matches confirmed diagnosis | | Formulary alternative is not appropriate | Prescriber letter: [reason — failed trial dated X / different approval scope / no formulary alternative exists] | | Clinical necessity | Specialist letter + current functional assessment |

Most formulary exceptions for rare-disease ERTs are resolved at the internal level when the prescriber letter is thorough.